Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17606391 | SELF-ASSEMBLING PROTEIN NANOCAGE DECORATED WITH ANTIBODIES (SAPNA) AND PARTS THEREOF | Final Rejection | The Regents of the University of California |
| 17046559 | MAMMALIAN MHC PEPTIDE DISPLAY AS AN EPITOPE SELECTION TOOL FOR VACCINE DESIGN | Non-Final OA | ETH Zürich |
| 17997742 | METHODS FOR DETECTION OF PATHOGENIC INFECTIONS USING RED BLOOD CELL-CONTAINING PATIENT SAMPLES | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18360631 | Methos for detection of microorganisms | Final Rejection | LABORATORY CORPORATION OF AMERICA HOLDINGS |
| 17923118 | MOLECULAR TRANSPORT FOR VIRAL AGENTS | Non-Final OA | McMaster University |
| 17913473 | FUSION PROTEIN AND METHOD OF DETECTING BACTERIA HAVING PSEUDAMINIC ACID | Non-Final OA | Academia Sinica |
| 17291879 | COMPOSITIONS AND METHODS | Final Rejection | Oxford University Innovation Limited |
| 17712600 | VACCINE AND THERAPEUTIC COMPOSITIONS COMPRISING ANTIGEN-CONJUGATED VIRAL CAPSIDS | Final Rejection | Board of Trustees of Michigan State University |
| 17924784 | RSV VACCINE BEARING ONE OR MORE P GENE MUTATIONS | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18583389 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CORONAVIRUS INFECTION USING AN IMMUNOMODULATOR AND VACCINE COMPOSITIONS COMPRISING THE SAME | Non-Final OA | ADVAGENE BIOPHARMA CO., LTD. |
| 18014934 | METHOD FOR DETERMINING THE RISK OF COMPLICATION IN A PATIENT | Non-Final OA | BIOASTER |
| 16964399 | HPV IMMUNOTHERAPY | Final Rejection | The Council of the Queensland Institute of Medical Research |
| 18379015 | COMPOSITIONS AND METHODS FOR TREATING PHENYLKETONURIA | Final Rejection | American Gene Technologies International Inc. |
| 18058169 | VIRAL NUCLEIC ACID MOLECULES, AND COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Centre for Virology, Vaccinology and Therapeutics Limited |
| 18245987 | HIGH THROUGHPUT METHODS AND PRODUCTS FOR SARS-COV-2 SERO-NEUTRALIZATION ASSAY | Non-Final OA | INSTITUT PASTEUR |
| 17802030 | METHOD FOR EVALUATING VIRAL CLEARANCE CAPABILITY | Final Rejection | ASAHI KASEI LIFE SCIENCE CORPORATION |
| 18100842 | IMMUNOGENIC COMPOSITION FORMING A VACCINE, AND A METHOD FOR ITS MANUFACTURE | Non-Final OA | ENGIMATA, INC |
| 17801055 | DESIGNER PEPTIDES AND PROTEINS FOR THE DETECTION, PREVENTION AND TREATMENT OF CORONAVIRUS DISEASE, 2019 (COVID-19) | Non-Final OA | United Biomedical, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy